tiprankstipranks
Advertisement
Advertisement

ANIP Stock Latest News

ANI Pharmaceuticals Shareholders Approve Amended 2022 Incentive Plan
Company AnnouncementsANI Pharmaceuticals Shareholders Approve Amended 2022 Incentive Plan
23h ago
8K
ANIP
ANI Pharmaceuticals Updates Investor Presentation, Highlights Non-GAAP Metrics
PremiumCompany Announcements
ANI Pharmaceuticals Updates Investor Presentation, Highlights Non-GAAP Metrics
9d ago
8K
ANIP
Analyst Reiterates Buy Rating After Earnings Beat and Raised Full-Year Guidance on Strong Cortrophin Gel Momentum
PremiumRatings
Analyst Reiterates Buy Rating After Earnings Beat and Raised Full-Year Guidance on Strong Cortrophin Gel Momentum
12d ago
ANIP
ANI Pharmaceuticals reports Q1 non-GAAP EPS $2.05, consensus $1.30
PremiumThe Fly
ANI Pharmaceuticals reports Q1 non-GAAP EPS $2.05, consensus $1.30
14d ago
ANIP
ANI raises FY26 adjusted EPS view to $9.19-$9.69 from $8.83-$9.34
PremiumThe Fly
ANI raises FY26 adjusted EPS view to $9.19-$9.69 from $8.83-$9.34
14d ago
ANIP
ANIP Earnings Report this Week: Is It a Buy, Ahead of Earnings?
PremiumPre-EarningsANIP Earnings Report this Week: Is It a Buy, Ahead of Earnings?
16d ago
ANIP
ANI Pharmaceuticals announces FDA approval, launch of Pimozide Tablets
Premium
The Fly
ANI Pharmaceuticals announces FDA approval, launch of Pimozide Tablets
1M ago
ANIP
ANI Pharmaceuticals launches Isosorbide Mononitrate Tablet USP
Premium
The Fly
ANI Pharmaceuticals launches Isosorbide Mononitrate Tablet USP
1M ago
ANIP
ANI Pharmaceuticals announces publication of iluvien clinical trial results
PremiumThe Fly
ANI Pharmaceuticals announces publication of iluvien clinical trial results
2M ago
ANIP
ANI Pharmaceuticals Highlights Updated Non-GAAP Metrics to Investors
PremiumCompany Announcements
ANI Pharmaceuticals Highlights Updated Non-GAAP Metrics to Investors
3M ago
8K
ANIP
ANI Pharmaceuticals Signals Strong Growth in 2025 Call
PremiumCompany Announcements
ANI Pharmaceuticals Signals Strong Growth in 2025 Call
3M ago
ANIP
ANI Pharmaceuticals Posts Record 2025 Results on Rare Disease Growth
PremiumCompany Announcements
ANI Pharmaceuticals Posts Record 2025 Results on Rare Disease Growth
3M ago
ANIP
ANI Pharmaceuticals reports Q4 adjusted EPS $2.33, consensus $1.98
PremiumThe FlyANI Pharmaceuticals reports Q4 adjusted EPS $2.33, consensus $1.98
3M ago
ANIP
ANI Pharmaceuticals sees FY26 adjusted EPS $8.83-$9.34, consensus $8.64
Premium
The Fly
ANI Pharmaceuticals sees FY26 adjusted EPS $8.83-$9.34, consensus $8.64
3M ago
ANIP
ANIP Upcoming Earnings Report: What to Expect?
Premium
Pre-Earnings
ANIP Upcoming Earnings Report: What to Expect?
3M ago
ANIP
ANI Pharmaceuticals price target raised to $124 from $115 at Guggenheim
PremiumThe Fly
ANI Pharmaceuticals price target raised to $124 from $115 at Guggenheim
4M ago
ANIP
ANI Pharmaceuticals issues strong 2025 preliminary results, 2026 outlook
PremiumCompany Announcements
ANI Pharmaceuticals issues strong 2025 preliminary results, 2026 outlook
4M ago
8K
ANIP
ANI Pharmaceuticals sees FY26 revenue $1.055B-$1.115B, consensus $955.04M.
PremiumThe Fly
ANI Pharmaceuticals sees FY26 revenue $1.055B-$1.115B, consensus $955.04M.
4M ago
ANIP
ANI Pharmaceuticals sees FY23 EPS, revenue ‘within or above guidance ranges’
PremiumThe Fly
ANI Pharmaceuticals sees FY23 EPS, revenue ‘within or above guidance ranges’
4M ago
ANIP
ANI Pharmaceuticals Announces Leadership Transition in Board
PremiumCompany AnnouncementsANI Pharmaceuticals Announces Leadership Transition in Board
6M ago
8K
ANIP
ANI Pharmaceuticals chairman Patrick Walsh to retire, Thomas Haughey to succeed
Premium
The Fly
ANI Pharmaceuticals chairman Patrick Walsh to retire, Thomas Haughey to succeed
6M ago
ANIP
ANI Pharmaceuticals Highlights November 2025 Financial Strategies
Premium
Company Announcements
ANI Pharmaceuticals Highlights November 2025 Financial Strategies
6M ago
8K
ANIP

Trending

Name
Price
Price Change
SPX
S&P 500
―
DJIA
Dow Jones
―
NDX
Nasdaq 100
―
More Trending Stocks >